These results confirm that 753b is a dual BCL-xL/2 degrader that can be more potent against BCL-xL/2 co-dependent SCLC cells than DT2216 alone and does not require combination with venetoclax to effectively kill these cells. This evidence concerns the gene BCL2L1 and small cell lung carcinoma.